Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Nelipepimut-S (Primary) ; Sargramostim; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 28 Sep 2017 According to a Galena Biopharma media release, interim efficacy analysis is scheduled to be performed by the Data Safety Monitoring Board (DSMB) in the first quarter of 2018. Results from the primary endpoint of the trial are expected in the fourth quarter of 2019.
- 28 Sep 2017 Status changed from recruiting to active, no longer recruiting according to a Galena Biopharma media release.
- 12 Jul 2017 According to a Galena Biopharma media release, 293 of the 300 patients are enrolled in the study.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History